CUV Share Price Performance
AU$0
-12.15 (-100.00%)
Price AU$0
Fair ValueAU$37.25
Share Pricen/a
Why Clinuvel Pharmaceuticals' (ASX:CUV) Earnings Are Better Than They Seem
Sep 03
Clinuvel Pharmaceuticals Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 113 Fair Values set on narratives written by author
CUV Community Narratives
AN
Fair Value AU$37.25 66.2% undervalued intrinsic discount
Rising Healthcare Expenditure And Aging Population Will Drive SCENESSE Uptake
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value AU$23.87 47.3% undervalued intrinsic discount
Phase III Trials And Health Canada Approval Will Advance Healthcare
5users have liked this narrative
0users have commented on this narrative
69users have followed this narrative
AN
Fair Value AU$14 10.1% undervalued intrinsic discount
Regulatory Risks Will Challenge Operations Yet Canada Will Buoy Prospects
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Rising Healthcare Expenditure And Aging Population Will Drive SCENESSE Uptake
Key Takeaways Strong physician engagement and first-mover status position Clinuvel for deeper market penetration and high-margin recurring revenue beyond analyst expectations. Robust financial health enables strategic acquisitions, accelerated R&D, and resilience to sector volatility, supporting sustained long-term growth.Read more
27
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
AU$37.25
66.2% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
65.39% p.a.
Profit Margin
38.33%
Future PE
13.65x
Price in 2028
AU$44.71
Phase III Trials And Health Canada Approval Will Advance Healthcare
Key Takeaways Expansion into new medical indications and pipeline diversification reduces reliance on a single product and supports long-term growth in rare disease markets. Strong reinvestment in R&D, commercial infrastructure, and new product launches positions the company for sustained earnings growth and mitigates funding and market risks.Read more
370
users have viewed this narrative5users have liked this narrative
0users have commented on this narrative
69users have followed this narrative
AN
AU$23.87
47.3% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
23.28% p.a.
Profit Margin
38.92%
Future PE
20.8x
Price in 2028
AU$28.65
Regulatory Risks Will Challenge Operations Yet Canada Will Buoy Prospects
Key Takeaways Heavy reliance on a single core product and heightened regulatory scrutiny present significant risks to revenue stability and future earnings potential. Expanding R&D and clinical initiatives may not guarantee commercial success amid rising competition and unpredictable approval or reimbursement outcomes.Read more
43
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
AU$14
10.1% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
5.55% p.a.
Profit Margin
28.15%
Future PE
26.87x
Price in 2028
AU$16.8
Trending Discussion
Recently Updated Narratives
AN
Phase III Trials And Health Canada Approval Will Advance Healthcare
Fair Value: AU$23.87 47.3% undervalued intrinsic discount
69 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Regulatory Risks Will Challenge Operations Yet Canada Will Buoy Prospects
Fair Value: AU$14 10.1% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rising Healthcare Expenditure And Aging Population Will Drive SCENESSE Uptake
Fair Value: AU$37.25 66.2% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Clinuvel Pharmaceuticals Limited Key Details
About CUV
- Founded
- 1999
- Employees
- n/a
- CEO
- WebsiteView website
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
